Title
Category
Credits
Event date
Cost
  • CMHC
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Immune thrombocytopenic purpura (ITP) is an autoimmune bleeding disorder that is characterized by suboptimal platelet count, purpura and hemorrhage. The burden of ITP is significant, leading to considerable mortality and life-threatening events such as intracranial hemorrhage and septicemia, if untreated, as well as reduction in health-related quality of life.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
ATTR cardiac amyloidosis (ATTR-CM) is a complex disease that remains challenging to diagnose and treat, and disproportionally affects African American patients. Low awareness about the disease, and limited therapeutic options are significant barriers to optimal care, however, significant advances have been made in the development of novel targeted-therapeutics that may improve patient outcomes. This clinical brief will review some of those advances in order to increase awareness about current gaps and disparities in ATTR-CM.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
Patients with a recent myocardial infarction (MI) are at very high-risk for future atherosclerotic cardiovascular disease (ASCVD) events, however, targeted LDL-C goal achievement and optimization of lipid lowering therapy (LLT) in these patients remains suboptimal. In turn, these gaps perpetuate the risk of future adverse events that patients with a recent MI will experience.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
Recent advances in the understanding of CKD progression in patients with type 2 diabetes have opened up new avenues of treatment that can potentially address some of the challenges and decrease cardiorenal risk in these patients. Of note, novel non-steroidal mineralocorticoid receptor antagonists (MRAs) are important new agents in this setting and have been recently FDA approved. During this activity, experts will discuss the recent advances with nonsteroidal MRAs in patients with type 2 diabetes and CKD, as well as their potential application to patient care.
  • LivDerm
  • TME
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Timely and adequate treatment of atopic dermatitis (AD) is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions.
  • LivDerm
  • TME
  • AAPA Category I CME
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pediatric patients with melanin-rich skin, or skin of color (SOC), can be disproportionately affected by numerous dermatologic conditions. Patients can be more susceptible or have a greater disease burden, especially with conditions such as acne, atopic dermatitis, psoriasis, pigmentary disorders, and hair disorders.
  • LivDerm
  • TME
  • AAPA Category I CME
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
In the United States, a rare disease is defined as a condition that affects fewer than 200,000 people in the US. While each rare disease may not seem to affect so many people, there may be as many as 7,000 rare diseases affecting an estimated 25-30 million Americans. More specifically, there over 1,000 rare skin diseases that are often an extreme burden to the collective many of patients affected by these conditions.
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Psoriatic arthritis (PsA) is a chronic, debilitating inflammatory disease that is associated with several comorbidities and often antecedes psoriasis. In fact, according to data from the National Psoriasis Foundation (NPF), approximately 30% of people with psoriasis develop PsA, with symptoms appearing around 10 years after the occurrence of cutaneous symptoms.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
Lowering LDL-C effectively and safely is paramount to prevent and lower the risk of recurrent ASCVD events. Even with the advances in LDL-C lowering therapy, LDL-C goal achievement is low, and clinical inertia and patient non-adherence are major factors for continued ASCVD residual risk. The landscape of LDL-C lowering therapy is rapidly evolving, with several new and emerging agents that may help address these gaps.
  • CMHC
  • TME
$0.00
The increasing prevalence and impacts of overweight and obesity in patients with type 2 diabetes renders weight loss and weight loss maintenance an important part of treatment goals. In this 6-part webcast series, chaired by Robert H. Eckel, MD and Donna Ryan, MD, you will have a chance to hear from experts on the comprehensive management of obesity in patients with type 2 diabetes, including lifestyle modifications, the spectrum of pharmacotherapy and metabolic surgery, as well as how to practically apply these concepts to patient care.

Pages